Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso
| Autor: | Arsène Zongo, Edwige T Yelemkoure, Isabelle Touwendpoulimdé Kiendrebeogo, Madeleine K. Kabré, Florencia Djigma, Jacques Simpore, Théodora Mahoukèdè Zohoncon, Albert Théophane Yonli, Abdoul Karim Ouattara, Dorcas Obiri-Yeboah, Hermann Karim Sombié, M. Zeba, Abel Pegdwendé Sorgho, Abdou Azaque Zoure, Prosper Bado, Issoufou Tao |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Hepatitis c viral
Genotype business.industry Specialties of internal medicine Hepacivirus Hepatitis C Chronic Viral Load Virology Antiviral Agents Hepatitis C Infectious Diseases Treatment Outcome RC581-951 Seroepidemiologic Studies Burkina Faso Medicine Seroprevalence Humans In patient Drug Therapy Combination Sofosbuvir business Genotyping |
| Zdroj: | Intervirology (2021) |
| ISSN: | 1423-0100 |
| Popis: | Introduction: Hepatitis C virus (HCV) infection remains a major public health problem worldwide. In Burkina Faso, nearly 720,000 people are living with HCV, and each year about 900 people die from complications of cirrhosis or hepatocellular carcinoma. This study was planned to determine the HCV seroprevalence, characterize circulating genotypes, and monitor HCV viral loads in patients under treatment with antivirals. Methods: A total of 4,124 individuals and 167 patients in the pre-therapy program were recruited. The “SD Bioline HCV” kit was used for rapid screening of anti-HCV antibodies. Viral load and genotyping were performed in 167 HCV patients on antivirals using the “Iontek HCV Quant” and “Iontek genotyping” kits. Results: Prevalence of HCV was 1.65% (68/4,124), and the median viral load of participants was 5.37 log10/mL (1.32–7.67 log10/mL). Genotype 2 was predominant with a frequency of 86.23% (144/167) and appeared to be more active with higher viral load compared to 13.77% (23/167) for genotype 1 (p < 0.001). After 24 weeks of pan-genotypic direct-acting antivirals, such as sofosbuvir/daclatasvir and sofosbuvir/velpatasvir, the viral loads of all patients became undetectable. Conclusion: The responses to antivirals by the circulating genotypes indicate that the results are very satisfactory. Therefore, the prevalence of HCV in the population can be reduced through identification of cases and treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|